| Accession |
PRJCA002283 |
| Title |
Metastatic melanoma phase II trial |
| Relevance |
Medical |
| Data types |
Exome
Transcriptome or Gene expression
Raw sequence reads
|
| Organisms |
Homo sapiens
|
| Description |
This multi-center, open-label, phase II study was designed to evaluate safety and efficacy of toripalimab in advanced Chinese melanoma patients who have failed systemic treatments. The primary objective was safety and objective response rate. Secondary objectives included duration of response, progression free survival, overall survival and immunogenicity. |
| Sample scope |
Multiisolate |
| Release date |
2020-03-26 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 32487680
|
PD-1 Blockade in Chinese versus Western Patients with Melanoma
|
Clinical Cancer Research
|
10.1158/1078-0432.CCR-20-1558
|
2020
|
| 32321714
|
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
|
Clinical Cancer Research
|
10.1158/1078-0432.CCR-19-3922
|
2020
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Beijing Cancer Hospital
|
|
2018S00663
|
|
|
|
| Submitter |
ling
xiao (ling_xiao@junshipharma.com)
|
| Organization |
Shanghai Junshi Biosciences Co., Ltd. |
| Submission date |
2020-02-26 |
